95 related articles for article (PubMed ID: 21036600)
21. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
[TBL] [Abstract][Full Text] [Related]
22. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
Yan TD; Boyer M; Tin MM; Wong D; Kennedy C; McLean J; Bannon PG; McCaughan BC
J Thorac Cardiovasc Surg; 2009 Sep; 138(3):619-24. PubMed ID: 19698846
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
25. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
26. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
27. Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
Steer J; Bough G; Razak AR; Meachery GJ; Hughes A
Clin Oncol (R Coll Radiol); 2010 Apr; 22(3):231-5. PubMed ID: 20346340
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
[TBL] [Abstract][Full Text] [Related]
29. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
30. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
31. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.
Busacca S; Sheaff M; Arthur K; Gray SG; O'Byrne KJ; Richard DJ; Soltermann A; Opitz I; Pass H; Harkin DP; Quinn JE; Fennell DA
J Pathol; 2012 Jun; 227(2):200-8. PubMed ID: 22190288
[TBL] [Abstract][Full Text] [Related]
33. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
Grigoriu BD; Chahine B; Vachani A; Gey T; Conti M; Sterman DH; Marchandise G; Porte H; Albelda SM; Scherpereel A
Am J Respir Crit Care Med; 2009 May; 179(10):950-4. PubMed ID: 19201924
[TBL] [Abstract][Full Text] [Related]
34. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
Frauenfelder T; Tutic M; Weder W; Götti RP; Stahel RA; Seifert B; Opitz I
Eur Respir J; 2011 Jul; 38(1):162-8. PubMed ID: 21273389
[TBL] [Abstract][Full Text] [Related]
35. Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
Jennings CJ; Murer B; O'Grady A; Hearn LM; Harvey BJ; Kay EW; Thomas W
Br J Cancer; 2015 Jun; 113(1):69-75. PubMed ID: 26057448
[TBL] [Abstract][Full Text] [Related]
36. miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.
Kresoja-Rakic J; Szpechcinski A; Kirschner MB; Ronner M; Minatel B; Martinez VD; Lam WL; Weder W; Stahel R; Früh M; Cerciello F; Felley-Bosco E
Noncoding RNA; 2019 Jun; 5(2):. PubMed ID: 31212997
[TBL] [Abstract][Full Text] [Related]
37. Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
Walter RF; Vollbrecht C; Werner R; Mairinger T; Schmeller J; Flom E; Wohlschlaeger J; Barbetakis N; Paliouras D; Chatzinikolaou F; Adamidis V; Tsakiridis K; Zarogoulidis P; Trakada G; Christoph DC; Schmid KW; Mairinger FD
J Cancer; 2016; 7(13):1915-1925. PubMed ID: 27698933
[TBL] [Abstract][Full Text] [Related]
38. [Neo-adjuvant chemotherapy of malignant tumors (based on the materials presented on the 9th congress of the oncologists of the Ukraine)].
Savran VR; Nekhme A; Savran VV
Klin Khir; 1998; (5):36-40. PubMed ID: 9787572
[No Abstract] [Full Text] [Related]
39. [Is it possible to consider a biological treatment of senescence].
BOURLIERE F
Gaz Med Fr; 1958 May; 65(10):925-6. PubMed ID: 13548371
[No Abstract] [Full Text] [Related]
40. [Prophylaxis for senescence].
MERLEN JF; FOSSATI P
Echo Med Nord; 1954 Mar; 25(3):146-52. PubMed ID: 13161835
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
